Brainstorm Cell Therapeutics Inc., of New York, said the Cleveland Clinic will be the first U.S. clinical site contracted for a planned phase II open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive multiple sclerosis.